Dr. Daniel George on the Treatment Landscape for RCC

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.

      Recent Videos
      Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
      Incentivizing RCC Research Investment Across Lower-Income Countries
      Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
      Identifying Regional Kidney Cancer Needs Via International Collaboration
      Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
      Using Biopsies to Inform Response Characteristics in Kidney Cancer
      Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
      Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
      Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
      Kidney Cancer Research Consortium Efforts May Improve Treatment Outcomes
      An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
      Kidney Cancer Research Program May Play Pivotal Role in Advancing Care
      Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
      Connecting With Congress to Advance Kidney Cancer Research
      Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
      Collaboration and Research Funding Advancements in Kidney Cancer Advocacy
      A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
      Radiologic Assessment May Be Used Before First Line Therapy for mccRCC
      A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
      Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney Cancer
      Related Content
      Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

      FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

      Russ Conroy
      February 26th 2025
      Article

      Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
      March 7th 2025
      Podcast

      A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

      LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

      Belzutifan Receives European Approval in Localized/Advanced RCC Indications

      Roman Fabbricatore
      February 18th 2025
      Article

      LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

      Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

      Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

      Eric Jonasch, MD
      February 3rd 2025
      Podcast

      Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

      Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

      Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

      Ariana Pelosci
      February 15th 2025
      Article

      Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.

      Nivolumab/Cabozantinib Demonstrates Long-Term Efficacy in Advanced RCC

      Nivolumab/Cabozantinib Demonstrates Long-Term Efficacy in Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Nivolumab plus cabozantinib yielded a median PFS of 16.4 months compared with 8.3 months from sunitinib alone in the first-line treatment of patients with advanced RCC.